Paradigm Biopharmaceuticals Ltd. yakashuma kuti zvidzidzo zvekutanga zvakaitwa uye zvakaiswa muUnited States (US) muPARA_OA_002 pivotal clinical trial, evaluating injectable pentosan polysulfate sodium (PPS/Zilosul®) yekurapa marwadzo ane chokuita nemabvi osteoarthritis (kOA). ) Chidzidzo chekutanga randomisation chakasimbiswa kuNorthwestern University, Chicago, neMutungamiriri weMuongorori, Dr. Thomas Schnitzer MD, Ph.D.
Iyo yepasi rose yakakosha Phase III, PARA_OA_002, kudzidza parizvino iri kuongorora uye kunyoresa vanhu munzvimbo sere dzeAustralia uye makumi maviri nerimwe enzvimbo makumi mashanu nenhanhatu dzakasarudzwa muUS Clinical trial site activation yave yakanyanya kutariswa neParadigm kubva pakutanga kwegore rekarenda kuti igonese. dziva hombe revanogona kuvhoterwa kuti vaonekwe munzvimbo dzese dzakaitwa uye vatange maitiro ekuongorora. Saiti activation muUS ichaenderera mberi, uye UK neEU masaiti ari kutangwa mukati meCY21.
"Kuita kuti zvidzidzo zvedu zvekutanga zviitwe zvisina tsarukano muUS chiitiko chakakosha muchirongwa chekiriniki yeOA. Chikwata chekiriniki cheParadigm changa chichishanda nesimba kutanga nekushandura masayiti muUS yese, uye tiri kuona nhamba huru yezvidzidzo zviri kupinda muchikamu chekuongorora muUS yese Tinotarisira kuenderera mberi nekusimba kwakasimba muchirongwa chePhase III uye kuzivisa kukosha kwekutora basa. zviitiko zvakakosha kune vatinogovera,” vakadaro Dr. Donna Skerrett, Chief Medical Officer weParadigm uye Interim CEO.
ZVOKUBVA MUNYAYA INO:
- Chidzidzo chepasi rose chakakosha Phase III, PARA_OA_002, parizvino chiri kuongorora nekunyoresa zvidzidzo munzvimbo sere muAustralia uye 21 pa56 nzvimbo dzakasarudzwa muU.
- Kliniki yekuedza saiti activation yanga iri yakakosha kutarisa kweParadigm kubva pakutanga kwegore rekarenda kugonesa dziva rakakura revanogona kuvhoterwa kuti vaonekwe munzvimbo dzese dzakaitwa uye kutanga maitiro ekuongorora.
- Iyo Paradigm kiriniki timu yanga ichishanda nesimba kutanga uye kumisikidza masaiti muU.
